The two companies, known for their vaccines, could see their businesses benefit from a yearly COVID-19 shot.
Companies whose businesses were buoyed or boosted by Covid product demand are facing a cliff in 2023, and will have to pivot to more traditional strategies.
Novavax (NASDAQ: NVAX) has offered investors just such a ride over the past few years. Initial gains came as investors bet on Novavax's chances of bringing a coronavirus vaccine to market; declines occurred after the vaccine entered the market later than rival products did. Now, as we start a new year, you might be wondering what to do about Novavax.